Transcatheter Mitral Valve Therapies
As one of the highest volume and most experienced transcatheter mitral valve programs in the nation, Northwestern Medicine continues to expand its Transcatheter Heart Valve Program by offering a wide array of minimally invasive commercially available and clinical trial options to treat the mitral valve, including MitraClip.
Transcatheter Mitral Heart Valve Therapies: MitraClip, Now Helping More Patients
The Transcatheter Heart Valve Program at Northwestern Medicine offers a wide variety of commercially available (FDA approved) and clinical trial options for the mitral valve, allowing us to tailor treatment precisely to each patient’s individual needs. For some patients with mitral valve disease, transcatheter heart valve therapies, like MitraClip, are an alternative treatment to open heart valve surgery.
In 2013, the U.S. FDA approved MitraClip for patients with degenerative or primary mitral regurgitation caused by disease of the mitral valve. In 2019, results from the COAPT™ clinical trial results1 showed that treatment with MitraClip leads to a reduction in hospitalizations and death compared to medical therapy alone.
|COAPTTM Clinical Trial Results1: MitraClip vs. Medical Therapy in Advanced Heart Failure Patients with Secondary or Functional Mitral Regurgitation
| MitraClip + Medical Therapy
||Medical Therapy Alone
| Annualized HF hospitalizations
|| 35.8% (lower number is better)
| All-Cause Mortality (death)
|| 29.1% (lower number is better)
| Alive and Moderately Improved Quality of Life2
|| 36.4% (higher number is better)
| Alive and Substantially Improved Quality of Life2
|| 29.1% (higher number is better)
As a result of these findings, the FDA approved MitraClip for patients with functional or secondary mitral regurgitation caused by diminished heart function. This approval has significantly expanded the number of people who can be treated with MitraClip.
As a leader in transcatheter mitral valve treatment options, Northwestern Memorial Hospital not only has one of the highest-volume MitraClip programs in Illinois3, but is also active in training physicians across the country on this and other advanced techniques.
Transcatheter Mitral Valve Commercially Available Treatment Options
Transcatheter procedures allow the procedure to be performed while the patient’s heart is still beating, eliminating the need for a “heart bypass” machine and its associated risks. Due to the minimally invasive nature of transcatheter procedures, patients tend to recover faster and experience an improvement in symptoms soon after the procedure is completed. The Transcatheter Heart Valve Program at Northwestern Medicine offers two mitral valve transcatheter treatment options: MitraClip and transcatheter mitral valve in valve replacement.
MitraClip: A minimally invasive treatment option for patients with mitral regurgitation. In patients with mitral regurgitation, the mitral valve does not close completely, allowing blood to flow backward or “leak,” creating symptoms that may include shortness of breath, fatigue and chest pain. MitraClip is the only device currently approved by the FDA for transcatheter mitral valve replacement (TMVR).
During MitraClip implantation, an interventional cardiologist inserts a catheter (tube) in the body through the femoral (groin) vein. The MitraClip device is compressed and advanced by a catheter through the vein until it reaches the diseased mitral valve. Once in the heart, the MitraClip device is positioned to join or “clip” together a portion of the mitral valve, reducing or eliminating the backward flow of blood.
Transcatheter Mitral Valve in Valve Replacement: A minimally invasive TMVR procedure for patients who have had previous open heart valve surgery to replace the mitral valve with a bioprosthetic/tissue valve and the valve is now failing. Instead of the failing mitral valve being replaced during another open heart valve surgery, the failing mitral valve is replaced by placing a TMVR valve inside the failing mitral valve.
During mitral valve in valve replacement, an interventional cardiologist and/or a cardiac surgeon inserts a catheter (tube) through a vein in the body. The TMVR valve is compressed and advanced by a catheter through a vein until it reaches the failing mitral valve. A balloon on the catheter expands and secures the TMVR valve within the failing mitral valve. The catheter is then removed and the secured TMVR valve remains in place pushing the failing mitral tissue valve out of the way, allowing the TMVR valve to take over the job of regulating blood flow from the heart.
Transcatheter Mitral Valve Clinical Trial Options
Researchers at Northwestern Medicine conduct clinical trials that provide access to innovative therapies for the treatment of heart and vascular disease. Participating in a clinical trial is an opportunity to evaluate the effectiveness and safety of medications or study devices. The study devices and delivery systems used in the following clinical trials are investigational (experimental), which means they are not approved for commercial use by the U.S. FDA.
PARTNER 3 Mitral Valve in Valve: enrolling patients who have some (intermediate) risk for undergoing open heart surgery and have an existing bioprosthetic mitral valve that is failing and needs to be replaced. Eligible participants will receive the SAPIEN 3 transcatheter heart valve (study device) to replace the failing bioprosthetic mitral valve.
APOLLO: enrolling patients to evaluate the Intrepid Transcatheter Mitral Valve Replacement (TMVR) System (study device) in people with severe, symptomatic mitral regurgitation. Eligible participants will be randomized to receive a TMVR using the Intrepid valve, and the other group will receive traditional open heart mitral valve surgery.
EVOQUE: enrolling patients to evaluate the Edwards EVOQUE Transcatheter Mitral Valve Replacement System (study device) in high surgical risk patients with moderate to severe mitral regurgitation. The EVOQUE valve is designed to replace the mitral heart valve without open heart surgery.
PASCAL CLASP IID: enrolling patients to evaluate the Edwards PASCAL Transcatheter Mitral Valve Repair System (PASCAL System) (study device) in patients with symptomatic degenerative mitral regurgitation who have been determined to be at prohibitive risk for mitral valve surgery. Eligible participants will be randomized to have the PASCAL System and the other group will receive the FDA-approved MitraClip System. The PASCAL System and the MitraClip System are designed to reduce the amount of mitral regurgitation without the need for surgery (less invasive).
Northwestern Medicine is also among the most experienced programs in the country for transcatheter treatment options for the aortic valve and tricuspid valve.
1. Health Status After Transcatheter Mitral Valve Repair in Patients with Heart Failure and Secondary Mitral Regurgitation: COAPT Trial. JACC, 2019.
2. Health status evaluated at baseline, 1, 6, 12, and 24 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ) and the Medical Outcomes Study Short Form 36 (SF-36) Health Survey.
3. IL IP COMPdata FY16 October-FY18 June YTD, last accessed December 2018.